Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658355 | PMC |
| http://dx.doi.org/10.4103/0019-5049.108589 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vitro activity of cefepime-tazobactam against oxyimino cephalosporin-resistant clinical isolates of E. coli: exploring a potential carbapenem-sparing strategy.
Eur J Clin Microbiol Infect Dis
January 2025
Department of Medical Microbiology, PGIMER, Chandigarh, Chandigarh, 160012, India.
Cefepime-tazobactam (FEP-TAZ) consists of cefepime combined with tazobactam, a penicillanic acid-sulfone recognized as an established beta-lactamase inhibitor. This study aims to investigate the in-vitro effectiveness of FEP-TAZ against cefepime-resistant clinical isolates of Escherichia coli (E. coli).
View Article and Find Full Text PDFDiscovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers.
J Med Chem
January 2025
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
SMARCA2 is an attractive synthetic lethal target in human cancers with mutated, inactivated SMARCA4. We report herein the discovery of highly potent and selective SMARCA2 PROTAC degraders, as exemplified by SMD-3236, which was designed using a new, high-affinity SMARCA ligand and a potent VHL-1 ligand. SMD-3236 achieves DC < 1 nM and > 95% against SMARCA2 and >2000-fold degradation selectivity over SMARCA4.
View Article and Find Full Text PDFAlphaviral genetic background of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen.
Mol Ther
December 2024
Michael Smith Laboratories, University of British Columbia, Vancouver, Canada V6T1Z4; School of Biomedical Engineering, University of British Columbia, Vancouver, Canada V6T1Z4. Electronic address:
Self-amplifying RNA (saRNA) vectors are a next-generation RNA technology that extends the expression of heterologous genes. Clinical trials have shown the dose-sparing capacity of saRNA vectors in a vaccine context compared to conventional messenger RNA. However, saRNA vectors have historically been based on a limited number of alphaviruses, and only the Venezuelan equine encephalitis virus-based saRNA vaccines have been used clinically.
View Article and Find Full Text PDFA novel mouse model of image-guided radiation-induced acute kidney injury using SARRP.
Biochem Biophys Res Commun
December 2024
Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea. Electronic address:
Radiation therapy is crucial for cancer treatment, but it often causes tissue damage. The kidney, which is sensitive to radiation, is under-researched in this context. This study aimed to develop a mouse model for radiation-induced acute kidney injury (AKI) using a small animal radiation research platform (SARRP) to mimic clinical radiation conditions.
View Article and Find Full Text PDFUltra-High Dose Rate Helium Ion Beams: Minimizing Brain Tissue Damage while Preserving Tumor Control.
Mol Cancer Ther
December 2024
National Center for Tumor Diseases, Heidelberg, Germany.
Ultra-high dose rate radiotherapy with electrons and protons has shown potential for cancer treatment by effectively targeting tumors while sparing healthy tissues (FLASH effect). This study aimed to investigate the potential FLASH sparing effect of ultra-high-dose rate helium ion irradiation, focusing on acute brain injury and subcutaneous tumor response in a preclinical in vivo setting. Raster-scanned helium ion beams were used to compare the effects of standard dose rate (SDR at 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!